Q4 2024 Earnings Call Transcript May 29, 2025 Roivant Sciences Ltd. misses on earnings expectations. Reported EPS is $-0.22 ...

Shares of Immunovant, Inc. (IMVT) traded 2% higher on Thursday morning after the company reported a narrower-than-expected ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Highlights in myasthenia gravis (MG) from the American Academy ... positive and muscle-specific tyrosine kinase-positive disease. He then turns to the ADAPT NXT trial, which compared fixed-cycle ...

Imaavy is the first FcRn blocker approved for anti-AChR and anti-MuSK antibody positive patients with generalized myasthenia gravis. The Food and Drug Administration (FDA) has approved Imaavy ...

Myasthenia gravis is termed a rare disease, but several pharma companies are battling for the market of more than 70,000 Americans with the neurological disorder. Titled “Imagine Your Zillions ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around. Researchers have ...

Myasthenia gravis (MG) is a chronic autoimmune condition that affects signaling between the body’s nerves and muscles, leading to muscle weakness. Symptoms of MG can appear anywhere on the body ...

Sunshine Cruz revealed that she was diagnosed with an autoimmune disease called myasthenia gravis, less than a week after her runway appearance at the “Body of Work” fashion show. Cruz opened ...

With that said, there is one program I want to zero in on, which is the development of its differentiated CD-19 CAR-T being developed to target patients with Myasthenia Gravis [MG]. The reason why ...

Neither the phase 3 myasthenia gravis data ... posting midphase Graves’ data and plotting next steps Immunovant has left the door open for batoclimab in thyroid eye disease.